Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2019-11-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "CEFIXIME CAPSULES"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the passing of a consistency evaluation for one of its pharmaceutical products. It is an announcement of a regulatory approval related to product quality and efficacy, not a financial report or detailed corporate filing. The document is short (2527 characters) and does not contain financial data, management discussion, or detailed report content. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance document. It is also not a notice of voting results, director dealings, or capital changes. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and quality evaluation, which does not fit into other specific categories.
2019-11-27 English
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0168 IN AUSTRALIA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the submission of a clinical trial application for a new investigational drug. It is an announcement of a specific event related to the company's drug development pipeline, not a financial report, regulatory filing, or management information. The document is relatively short (2866 characters) and focuses on a clinical trial application submission, which is a corporate update rather than a financial or governance report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2019-11-27 English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Results For the Nine Months Ended 30 September 2019' and contains detailed unaudited consolidated financial statements, including revenue, profit, segment information, earnings per share, and business review for the nine-month period ending 30 September 2019. It includes comprehensive financial data and analysis for a period shorter than a full fiscal year, which aligns with the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or publication notice. There is no indication that this is an Annual Report (10-K) or a simple earnings release (ER) since it contains detailed financial statements and segment analysis. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). 9M 2019
2019-11-18 English
VOLUNTARY ANNOUNCEMENT - PRODUCT TRANSFER AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding a product transfer agreement involving a subsidiary and another pharmaceutical company. It details the terms of the agreement, including rights, payments, and product information. The document is relatively short (3485 characters) and is an announcement of a corporate transaction rather than a full financial report or regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. The content fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's product portfolio and potential revenue streams. It is not a merger or acquisition filing (MA or TAR) since it is a product transfer agreement, not a merger or takeover. Therefore, the appropriate classification is CAP with high confidence.
2019-11-07 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the date of a board meeting to approve the unaudited third quarterly results for the nine months ended 30 September 2019. It does not contain the actual financial results or detailed financial data but merely informs about the upcoming board meeting where such results will be approved. The document length is short (1459 characters) and serves as a notification rather than a report. According to the classification rules, such announcements about meetings to approve financial results fall under Regulatory Filings (RNS) as they are general regulatory announcements and do not contain substantive financial data themselves.
2019-11-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2019
Major Shareholding Notification Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including ordinary shares, preference shares, share options, warrants, convertibles, and other share-related transactions for the month ended 31/10/2019. The document includes confirmations by a director regarding compliance with listing rules and legal requirements related to securities issued during the month. There are no financial statements, earnings data, or management discussion of financial results. The content focuses exclusively on share capital movements and confirmations related to securities issuance. This matches the characteristics of a Major Shareholding Notification or similar shareholding movement report. Given the detailed monthly movements in securities and share capital, the most appropriate classification is Major Shareholding Notification (MRQ).
2019-11-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.